The Effect of Inhibition of B7-mediated Costimulation on Allergic Airway Inflammation in Mild Atopic Asthmatics
Status:
Completed
Trial end date:
2012-02-01
Target enrollment:
Participant gender:
Summary
This study is designed to determine if treatment with abatacept is effective in decreasing
allergic airway inflammation in mild, atopic asthmatics. Subjects will be recruited from the
greater St Louis Metropolitan area. Eligible individuals will undergo a titrated skin prick
test. Following baseline evaluation, fiberoptic bronchoscopy with segmental allergen
challenge (SAC) will be performed. The subjects will be randomized to either placebo or
abatacept. After 12 weeks of study drug, the subjects will undergo repeat SAC. The primary
endpoint will be to determine if treatment with abatacept results in a 50% or greater
decrease in the percentage of eosinophils recovered in the bronchoalveolar lavage (BAL) fluid
following SAC as compared to placebo control. Secondary endpoints include measures of airway
obstruction and hyperreactivity, airway inflammation and symptoms as well as determination of
the safety of abatacept administration in this subject population.